Yes, and EM was aware of the different routes and focusing on the one they felt most likely qualified for when they made the statement.There are many different routes a company can take to get listed on NASDAQ. Not all of those routes involve strong revenues and profits. Many companies are just starting and trying to raise capital. Look at any small biotech company on the NASDAQ and you'll see they lose money year after year after year. At least Elio looks better than some of these biotech companies. Elio has 65,000 "patients" that want their product.
Elio will probably list under under "assets with equity", "market value standard, "equity standard", or "market value of listed securities standard". See link for all the details:
http://business.nasdaq.com/media/Nasdaq Initial Listing Guide_tcm5044-13919.pdf
The small biotech companies you mention likely aren't losing money, just not showing a profit. They have a continuous flow of revenue much of which goes back into the business for market expansion while continuing to meet the NASDAQ financial and as, or more, importantly the liquidity requirements.
EM's initial Reg A+ IPO is a prime example of a startup successfully raising $16Million of funding, $12Million of that earmarked specifically for the completion of the 25 prototypes and testing, a process that would take 4-6 months upon securing the funds.